PLA2G7 and atopic asthma: In a randomized, double-blind, placebo-controlled crossover trial [11], 14 subjects with mild atopic asthma received either recombinant human PAF-AH (ie, Lp-PLA2; target plasma concentration of >10 μg/mL) or placebo followed by exposure (inhaled) to subject-specific allergen (based on skin prick testing).